Main menu

Cancer clinical genomic testing using Oxford Nanopore whole-genome sequencing | LC26

  • Published on:

Abstract
Whole-genome sequencing (WGS) is currently offered as a routine genomic test for selected cancer clinical indications through the NHS Genomic Medicine Service. Here, we investigate the requirements to support the introduction of Oxford Nanopore Technologies (ONT) WGS into the NHS and assess the clinical benefits for cancer patients. Four hundred and ninety-nine tumour-normal pairs (brain, leukaemia, and sarcoma tumours) were sequenced with the PromethION platform across five NHS Genomics Laboratory Hubs. The quality of fresh frozen samples collected through clinical pathways was sufficient to generate high-depth coverage (tumour ≥40x, normal ≥20x) for accurate variant detection. Analysis of the underperforming samples identified key contributing factors, such as DNA extraction method, insufficient DNA, and fragmentation. Iterative improvements to our analytical pipeline led to high accuracy of detection for all types of genomic variants (sensitivity and specificity exceed 95%, except 89% sensitivity for indels). Methylation-based classification achieved 91% concordance with integrated pathology diagnosis for brain tumours. The strongest evidence of clinical utility emerged for brain tumours where ONT sequencing can consolidate multiple molecular tests including methylation profiling into a single workflow, minimizing turnaround times. For other tumours, ONT sequencing has shown promise in resolving complex cases, e.g. detecting clinically relevant events missed by other tests in about 10% of haematological tumours. Additional benefits included detection of mid-sized indels and variants in challenging genomic regions or cryptic chromosomal rearrangements, and phasing compound heterozygous variants. In summary, our study has demonstrated the value of ONT WGS, particularly a ‘one-stop-shop’ test for brain tumours as well as a second-line test for selected cancer cases.

Biography
Rowan Howell is a Senior Genomics Data Scientist at Genomics England, where he works on bioinformatics analysis of long-read genomics data. He completed a PhD in computational biology between the Francis Crick Institute and King’s College, London before conducting postdoctoral research at the Cancer Institute, UCL. While at Genomics England, Rowan has overseen analysis of the Cancer 2.0 long-reads project, examining the clinical utility of ONT for cancer genomics.

Authors: Rowan Howell

入门指南

购买 MinION 启动包 Nanopore 商城 测序服务提供商 全球代理商

联系我们

知识产权 Cookie 政策 企业报告 隐私政策 条件条款 Modern slavery policy 前瞻性陈述

关于 Oxford Nanopore

联系我们 领导团队 媒体资源和联系方式 投资者 在 Oxford Nanopore 工作 BSI 27001 accreditationBSI 90001 accreditation
Chinese flag